Monoclonal antibody therapy continues to have a major impact in the fight against COVID-19 with the potential to do more
JACKSON, Mississippi (WLBT) – When it comes to the fight against COVID-19, public health official Dr Thomas Dobbs has long preached that Plan A is vaccination and Plan B is antibody therapy monoclonal, with a strong emphasis on monoclonal acting as plan B.
“We’re a big fan of Mississippi monoclonal drugs, but the reduction in mortality is not as good as the vaccine,” Dr. Dobbs said. “You don’t get the best choice available to protect you. “
On Thursday, Dr Dobbs cited a study that found monoclonal drugs have prevented nearly 3,000 hospitalizations since June.
Thanks to MS Doctors, Hospitals, Clinics, KPMG and MSDH Team for their amazing work with monoclonal drugs. Based on published studies (~ 70% reduction in hospitalizations or deaths) – avoided nearly 3,000 hospitalizations since June!
MS still has a sufficient supply. https://t.co/xw3hGmfVbk pic.twitter.com/CHoLA3nbB3
– thomas dobbs (@TCBPubHealth) October 7, 2021
Baptist Memorial Healthcare infectious disease medical director Dr Steve Threlkeld said Baptist – as a whole – had distributed more than 17,000 doses of monoclonal drugs since mid-November.
“This reduces the incidence of serious illness and death by about 70%,” said Dr Threlkeld. “The vaccine reduces it by about 90 percent and is much better studied than even the monoclonal antibody.”
He said the therapy has been a life-saving intervention for those who do not have such a good antibody response to the vaccine, such as those who are immunocompromised.
“At a time when hospitals were overloaded and stressed by both staff and beds in the Southeastern United States, reducing hospitalizations and deaths by 70% is a huge, huge thing to say,” he said. said Dr Threlkeld.
He said monoclonal antibodies have been used for some time for cancer and immunosuppressive therapies. The pandemic has accelerated the pace of finding out what treatment is capable of, and Dr Threlkeld said it likely won’t go away anytime soon.
“I think a lot of cancer chemotherapy in the decades to come will be based on monoclonal antibodies,” he said. “You won’t see a lot of old-fashioned chemotherapy with the big toxicities.”
Dr Threlkeld says the provision of monoclonal antibodies is more of a concern than a “practical factor”. He said the national supply is not insufficient at the moment, but that much of that supply is used in the southeast, where cases remain high and vaccination rates low.
He said AstraZeneca published a new study on a long-acting monoclonal antibody. The European vaccine producer has found that it prevents COVID-19 infections by up to 77%, but there is still some research to be done before using it.
Mississippi Baptist Medical Center offers monoclonal antibody therapy Monday through Friday 8 a.m. to 5 p.m. and can deliver up to 62 treatments per day. To make an appointment, dial 855-733-8863.
Saint-Dominique Hospital also offers the therapy and made this statement on Friday in terms of effectiveness:
“Expanded access to monoclonal antibody treatments has been an invaluable tool in helping to prevent hospitalizations and deaths from COVID-19. Here in St. Dominic’s, we have been working as quickly as possible to make these treatments widely available in our St. Dominic Family Medicine and MEA clinics, as well as a dedicated COVID community treatment center in Flowood where individuals can access medical care. testing and treatment without needing a referral from another clinic or provider. Since the beginning of August, more than 2,200 people have received an infusion or an injection of Regeneron via a site in Saint-Dominique.
The University of Mississippi Medical Center also offers the treatment. To make an appointment, follow this link.
Treatment is only effective if received within 10 days of symptom onset.
Copyright 2021 WLBT. All rights reserved.